These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12230360)

  • 21. Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome).
    Calguneri M; Ozbalkan Z; Ozturk MA; Apras S; Ertenli AI; Kiraz S
    Clin Rheumatol; 2006 Nov; 25(6):782-8. PubMed ID: 16547692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bullous systemic lupus erythematosus induced by the therapy for lupus nephritis.
    Jedlickova H; Bohmová J; Sirotkova A
    Int J Dermatol; 2008 Dec; 47(12):1315-6. PubMed ID: 19126028
    [No Abstract]   [Full Text] [Related]  

  • 23. Trends of anticardiolipin antibodies after low-dose methylprednisolone and cyclophosphamide treatment of systemic lupus erythematosus.
    Lavalle-Graef A; Villegas-Acosta L; Lavalle C
    Arch Med Res; 2004; 35(5):421-7. PubMed ID: 15610913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
    Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H
    Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
    Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
    Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis.
    Chan TM
    Arthritis Rheum; 2007 Mar; 56(3):702-4. PubMed ID: 17328038
    [No Abstract]   [Full Text] [Related]  

  • 27. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide.
    Urowitz MB; Ibañez D; Ali Y; Gladman DD
    J Rheumatol; 2007 Jul; 34(7):1491-6. PubMed ID: 17610320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance therapy for lupus nephritis--something old, something new.
    Balow JE; Austin HA
    N Engl J Med; 2004 Mar; 350(10):1044-6. PubMed ID: 14999117
    [No Abstract]   [Full Text] [Related]  

  • 30. [Management of lupus nephritis in Senegal].
    Diouf B; Toure AO; Ka MM; Pouye A; Diop TM
    Dakar Med; 1997; 42(2):145-8. PubMed ID: 9827139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction and maintenance therapy in proliferative lupus nephritis.
    Ponticelli C; Glassock RJ; Moroni G
    J Nephrol; 2010; 23(1):9-16. PubMed ID: 20091481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The long-term prognosis of lupus nephritis patients treated with intravenous cyclophosphamide.
    Matsuyama N; Morimoto S; Tokano Y; Amano H; Nozawa K; Isonuma H; Hashimoto H; Takasaki Y
    Intern Med; 2010; 49(9):823-8. PubMed ID: 20453401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful control of scleroderma myocarditis using a combination of cyclophosphamide and methylprednisolone.
    Stack J; McLaughlin P; Sinnot C; Henry M; MacEneaney P; Eltahir A; Harney S
    Scand J Rheumatol; 2010 Aug; 39(4):349-50. PubMed ID: 20476869
    [No Abstract]   [Full Text] [Related]  

  • 34. Mycophenolate mofetil for lupus nephritis.
    McCune WJ
    N Engl J Med; 2005 Nov; 353(21):2282-4. PubMed ID: 16306526
    [No Abstract]   [Full Text] [Related]  

  • 35. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A.
    Ferrario L; Bellone M; Bozzolo E; Baldissera E; Sabbadini MG
    Rheumatology (Oxford); 2000 Feb; 39(2):218-220. PubMed ID: 10725082
    [No Abstract]   [Full Text] [Related]  

  • 36. Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.
    Fujinaga S; Kaneko K; Ohtomo Y; Murakami H; Takada M; Akashi S; Hira M; Yamashiro Y
    Pediatr Nephrol; 2005 Oct; 20(10):1500-3. PubMed ID: 16021476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Updates on the treatment of lupus nephritis.
    Bomback AS; Appel GB
    J Am Soc Nephrol; 2010 Dec; 21(12):2028-35. PubMed ID: 21051743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.
    Boletis JN; Ioannidis JP; Boki KA; Moutsopoulos HM
    Lancet; 1999 Aug; 354(9178):569-70. PubMed ID: 10470708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A girl with difficult lupus nephritis: lupus vasculopathy.
    Ma AL; Lai WM; Chiu MC; Tse NK
    Clin Exp Nephrol; 2012 Dec; 16(6):968-72. PubMed ID: 23135867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.